Compare BCBP & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | NERV |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.5M | 166.4M |
| IPO Year | 2005 | 2014 |
| Metric | BCBP | NERV |
|---|---|---|
| Price | $8.14 | $2.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $8.95 | ★ $10.33 |
| AVG Volume (30 Days) | ★ 469.9K | 135.5K |
| Earning Date | 10-26-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.31 | $2.31 |
| 52 Week High | $11.71 | $12.46 |
| Indicator | BCBP | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 35.76 | 22.50 |
| Support Level | $8.11 | N/A |
| Resistance Level | $8.84 | $5.69 |
| Average True Range (ATR) | 0.18 | 0.25 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 16.07 | 6.25 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.